BHCM
KPTI icon

Brevan Howard Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Brevan Howard Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
+212,367
New +$1.62M 0.01% 823
2023
Q4 		– Sell
-1,522
Closed -$30.6K – 1060
2023
Q3 		$30.6K Buy
+1,522
New +$34.2K ﹤0.01% 375

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Brevan Howard Capital Management's KPTI Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 212,367 shares worth $1.18M. The stake represents 0.01% of the portfolio and ranks #823 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in KPTI as recently as Q3 2023.

Brevan Howard Capital Management first reported a position in KPTI in Q3 2023 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Brevan Howard Capital Management held 212,367 shares of Karyopharm Therapeutics worth $1.18M as of Q1 2026.
  • Karyopharm Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • Karyopharm Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #823 holding.
  • Brevan Howard Capital Management first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.